Categories
- PROTAC Linker
- Protein Control Ligand
- Pathway Inhibitors
- Function Modulators
- Activators
- G Protein-Coupled Receptor Ligands
- Nuclear Receptor Ligands
- GDNF Receptors
- TNF Receptors
- Transcription Factors
- Chemokines
- Cytokine Receptors
- Biomarkers and Buffer Solutions
- Molecular Probes
- Stem Cell Research
- Alzheimer's Disease
- Apoptosis
- Cancer Research
- Epigenetics
- Metabolites
- PET/SPECT Imaging Precursors
- Customized Screening Library
- Ultra Pure Pharmacological Standard
- Tissue Microarray (TMA)
- Proteins and Antibodies
- Primary Cells
- ELISA KIT
- Natural Products
- Lab Equipments
- Humanized Mice for PDX Platform
- Rare Chemicals
- Custom Synthesis
- Antibacterial
- Antifungal
- Antioxidant
- Antiviral
- Molecular Glues
- SARS-CoV
Quantity Discount Table - Order More To Get More Price Discount
| Quantity | mg | Unit Price ($/mg or $/Unit) | Final Price |
|---|---|---|---|
| 1 | 5 | $78.20 | Total: $391.00 |
| 1 | 10 | $66.24 | Total: $662.40 |
| 1 | 25 | $56.12 | Total: $1,403.00 |
| 1 | 50 | $47.84 | Total: $2,392.00 |
| 1 | 100 | $41.40 | Total: $4,140.00 |
Overview
Utreloxastat (PTC857) is a novel 15-lipoxygenase inhibitor that can be used to study amyotrophic lateral sclerosis .
Chemical Properties
| Molecular Formula | C18H28O2 |
| Molecular Weight | 276.41 |
| CAS Numbers | 1213269-96-5 |
| Solubility | DMSO |
| Purity | 98% by HPLC |
| SMILES Code | CCCCCCCCCC1=C(C)C(=O)C(C)=C(C)C1=O |
Storage and Handling
0C Short Term, -20C Long Term
References
Gao L, Giannousis P, et al. First-in-Human Studies of Pharmacokinetics and Safety of Utreloxastat [PTC857], a Novel 15-Lipooxygenase Inhibitor for the Treatment of Amyotrophic Lateral Sclerosis. Clin Pharmacol Drug Dev. 2023 Feb;12[2] 141-151.